Alternatively, APP cleavage by cathepsin B followed by glutaminyl cyclase modification of the truncated Aβ (3–42) into pyroglutamate (pE)-modified Aβ3(pE)–42 may also contribute to AD pathology in other subgroups [21, 22]. This evidence concerns the gene APP and Alzheimer disease.